Bill Wilson, MD: Skyrocketing GLP-1 Prices Force Patients to Seek Affordable Alternatives #glp1
A short interview discussing concerns about rapidly rising prices of GLP-1 drugs for weight loss and diabetes, mention of specific branded drugs (Ozempic, tirzepatide), and the role of compounding pharmacies importing products from overseas. The conversation highlights cost and insurance coverage (insurers often cover diabetes treatments but not obesity), and questions whether patients should use branded GLP-1s or compounded alternatives.
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet